李子瑞,姜 军

小细胞肺癌（SCLC）作为肺癌中恶性程度较高的亚型，预后较差，5年生存率仅约5%。精准的预后评估对指导临床治疗、改善患者生存状况意义重大。血清神经元特异性烯醇化酶（NSE）是SCLC诊断、治疗监测和预后评估的重要标志物，其联合其他生物标志物能提高预后评估的准确性。本文系统综述了NSE联合常见生物标志物（如胃泌素释放肽前体、癌胚抗原、细胞角蛋白19片段等）在SCLC预后评估中的应用价值及研究进展，为临床实践提供参考。

小细胞肺癌；神经元特异性烯醇化酶；生物标志物；预后评估

[1] 刘庆丰,王芳.细胞角蛋白-19片段抗原､神经元特异性烯醇化酶､鳞癌抗原在非小细胞肺癌患者中的表达及其对化疗效果和预后的评估价值[J].肿瘤基础与临床,2025,38(02):169-172. [2] 范小波,郭静,李文,等.CT影像组学参数结合CEA,CYFRA21-1,SCC和NSE在肺癌分型及预后评估的应用价值[J].临床肺科杂志, 2025,30(04):513-519. [3] 高金锋,胡萍.白蛋白与碱性磷酸酶比值评估晚期非小细胞肺癌化疗疗效和预后的意义[J].中国临床研究,2025,38(03):379-382+388. [4] 吴二伟,乔伟丽,马耀先.小细胞肺癌患者CD56､INSM1表达情况及对预后的评估价值[J].淮海医药,2025,43(02):117-121. [5] 郭华,赵静,李丹丹.非小细胞肺癌组织中miR-148a-3p､EGFR及SCCAg的表达及其对预后的评估价值[J].实用癌症杂志,2025, 40(03):366-368+372. [6] 董树晓.血清CYFRA21-1联合NSE检测在非小细胞肺癌患者中的表达及临床意义[J].黑龙江医学,2025,49(05):596-599. [7] 梁杰,于瑞静,杨越.CA724､NSE及ProGRP在非小细胞肺癌化疗预后评估中的作用[J].感染､炎症､修复,2025,26(01):57-60. [8] 刘婷.血清HE4､CA153､CA724､NSE水平对非小细胞肺癌患者预后的评估价值[J].中国卫生工程学,2025,34(01):116-117+120. [9] 廖运国,唐梓瑜,邓丹,等.非小细胞肺癌组织USP44､NCOR1表达对预后的影响[J].国际检验医学杂志,2025,46(03):261-265. [10] 朱碧莲,郑勇,董科.18F-FDG PET/CT多参数对非小细胞肺癌预后评估的价值[J].浙江医学,2025,47(02):163-167+183+227. [11] 李明珠,江叶倩,王莹莹,等.SII､CRP/Alb及D-二聚体对PD-1抑制剂联合化疗的晚期非小细胞肺癌患者预后的评估价值[J].临床肺科杂志,2025,30(02):250-256. [12] 江山,王乐朋,陈大川,等.iSEND免疫评分联合LIPI在评估非小细胞肺癌免疫治疗预后中的价值[J].中国肿瘤生物治疗杂志, 2025,32(01):79-84. [13] 彭蓉蓉,卞家蓉,谈王蓉.血清神经元特异性烯醇化酶､基质细胞衍生因子1和诱饵受体3联合在非小细胞肺癌病人预后评估中的临床意义[J].临床外科杂志,2025,33(01):92-96. [14] Jia X,Wang Y,Zhang H,et al.Current status and quality of prognosis prediction models of non-small cell lung cancer constructed using computed tomography(CT)-based radiomics:a systematic review and radiomics quality score 2.0 assessment.[J].Quantitative imaging in medicine and surgery,2024,14(9):6978-6989. [15] Saal J,Bald T,Eckstein M,et al.Integration of on-treatment modified Glasgow prognostic score(mGPS)to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.[J].Lung cancer(Amsterdam, Netherlands),2024,189 107505-107505. [16] Wang J,Dai G,Ren X,et al.Assessing the reproducibility,stability,and biological interpretability of multimodal computed tomography image features for prognosis in advanced non‐small cell lung cancer[J].iRADIOLOGY,2024,2(1):3-16. [17] Wang H,Yang R,Cheng C,et al.Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy:A Meta-Analysis.[J].Nutrition and cancer,2024,76(2):187-195. [18] Khan O,Salluzzi M,Bridges R,et al.1362P Evaluation of imaging-based prognostication(IPRO)for advanced non-small cell lung cancer(aNSCLC)using deep learning applied to computed tomography(CT)[J].Annals of Oncology,2024,35(S2):S858-S858. [19] Murray J,Huang Q,Hu C,et al.1346P A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer(NSCLC)[J].Annals of Oncology,2024,35(S2):S851-S851. [20] Yamamoto M,Serizawa T,Sato Y,et al.Validity test of small cell lung cancer(SCLC)graded prognostic assessment and proposal of a new index for patients with brain metastases from SCLC[J].Clinical and Translational Radiation Oncology,2024,48 100820-100820. [21] Endo S,Imai H,Shiono A,et al.The Glasgow Prognostic Score as a Predictor of Survival After Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.[J].Oncology,2024, [22] Zhou Y,Wu Z,Wang H,et al.Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics[J].European Journal of Medical Research,2024,29(1):401-401. [23] Ozawa R,Sonehara K,Hachiya T,et al.Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer:A multicenter retrospective study.[J].Cancer medicine,2024,13(15):e70080. [24] 任婕,赵建清,袁胜芳,等.MRPL48在非小细胞肺癌中表达及对A549细胞增殖､凋亡的影响[J/OL].生物技术,1-5[2025-07-03]. [25] Su H,Yu C,Sun G,et al.Prognostic value of immunotherapy in advanced non-small cell lung cancer based on baseline and dynamic changes in hemoglobin,albumin,and platelets.[J].Biomolecules&biomedicine,2024, [26] Yang Y,Shao X,Li Z,et al.Prognostic heterogeneity of Ki67 in non-small cell lung cancer:A comprehensive reappraisal on immunohistochemistry and transcriptional data.[J].Journal of cellular and molecular medicine,2024,28(14):e18521. [27] Qiao H,Feng Y,Han X,et al.Values of a novel comprehensive prognostic nutritional index(FIDA)in the prognosis of non-small cell lung cancer[J].Frontiers in Oncology,2024,14 1393684-1393684. [28] Masse M,Chardin D,Tricarico P,et al.[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients:long term prognosis assessment and clinical management proposal.[J].European journal of nuclear medicine and molecular imaging,2024,51(12):3696-3708. [29] Grundberg O,Skribek M,Swerkersson S,et al.Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer:A prospective,single-arm,open-label,clinical trial(BevMar).[J].European journal of radiology,2024,177 111557. [30] Eklund A E,Mourad A,Wiel C,et al.Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer:a retrospective analysis[J].Frontiers in Oncology,2024,14 1396285-1396285.

点击下载PDF